Highlights Of The Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program 2026

DAY 1 :
WEDNESDAY, 2 SEPTEMBER, 2026
08:00 - 08:50
REGISTRATION AND MORNING REFRESHMENTS
08:50 - 09:00
OPENING ADDRESS
09:00 - 09:25
IP STRATEGY AND PATENT PROTECTION FOR DRUG DELIVERY TECHNOLOGIES
Balvinder Matharu
HGF Limited

Balvinder Matharu

HGF Limited

  • Protecting overall product exclusivity by strengthening delivery and formulation IP positions
  • Repurposing existing molecules through delivery innovation while managing patent strategy
  • Reviewing freedom-to-operate risks across oral, long-acting, and targeted platforms
09:25 - 09:30
Q&A SESSION ON IP STRATEGY FOR DRUG DELIVERY
09:30 - 09:55
EXOSOME-BASED DRUG DELIVERY: OPPORTUNITIES IN ENABLING PERSONALISED THERAPIES FOR BRAIN DISORDERS
Luís Valente
iLoF

Luís Valente

iLoF

  • Addressing challenges in developing brain-targeted personalised drug therapies
  • Exploring exosomes as natural carriers for CNS-targeted delivery strategies
  • Developing engineered exosomes for precise delivery in neurological disorders
09:55 - 10:00
Q&A SESSION ON EXOSOMES FOR BRAIN-TARGETED THERAPEUTICS
10:00 - 10:25
PATIENT-CENTRIC DESIGN FOR AUTOINJECTORS WITH LONGER INJECTION DURATIONS
Tom Lever
PA Consulting

Tom Lever

PA Consulting

  • Considering how larger volumes, higher viscosity, and slower rates extend autoinjector usage time
  • Reframing autoinjector design around comfort, usability, and confidence during longer injections
  • Adapting patient-centric features to support control, adherence, and acceptance with longer dosing
10:25 - 10:30
Q&A SESSION ON PATIENT-CENTRIC AUTOINJECTOR DESIGN
10:30 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON REVOLUTIONISING DRUG DELIVERY: INNOVATIONS IN WEARABLE AND IMPLANTABLE DEVICES
Speaker Image
  • Decoding the design complexity and organisational shifts required as drug delivery moves toward connected wearable and implantable systems
  • Overcoming manufacturing scale-up challenges for nanofibre-integrated wearables and implantables to achieve clinical viability
  • Benchmarking FDA-approved implantable sensor performance to evaluate clinical outcomes and inform next-generation device development
  • Harnessing AI and real-world data to bridge clinical innovation and payer acceptance of advanced delivery devices
  • Designing wearable adherence into connected devices without compromising patient autonomy or creating surveillance-driven care

Mayur Patel | PA Consulting

Promise Ayomide Adekola | University of Huddersfield

Thomas J Webster | Brown University

Sabine Kapasi | Enira Consulting

Morven Shearlaw | Fearsome

11:30 - 11:55
TAILORED CAPSULE TECHNOLOGIES FOR TODAY'S KEY FORMULATION CHALLENGES
Ricardo Figueiredo
Lonza

Ricardo Figueiredo

Lonza

  • Mitigating oxidation risks, ingredient incompatibilities, and solubility challenges through off-the-shelf and speciality capsule technologies
  • Customising capsule-in-capsule and lipid-based systems to deliver poorly soluble APIs and therapeutic peptides with enhanced bioavailability
  • Optimising targeted enteric delivery and permeation strategies using engineered capsules without post-filling coating requirements
11:55 - 12:00
Q&A SESSION ON CAPSULE-ENABLED FORMULATION SOLUTIONS FOR COMPLEX THERAPEUTICS
12:00 - 12:25
VYXEOS AND LIPOSOMAL DRUG DELIVERY: TRANSLATING FORMULATION INNOVATION INTO HAEMATOLOGICAL CLINICAL OUTCOMES
Barbara Siha
The London Clinic

Barbara Siha

The London Clinic

  • Demonstrating CPX-351 as a fixed-ratio liposomal platform with proven impact in AML
  • Contrasting liposomes with ADCs, biologics, and targeted agents across delivery and toxicity
  • Translating formulation innovation into practice through preparation and toxicity management
  • Anticipating hybrid and personalised delivery strategies that could reshape haematology care
12:25 - 12:30
Q&A SESSION ON LIPOSOMAL DELIVERY IN HAEMATOLOGY
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE EUROPEAN DRUG DELIVERY SUMMIT
13:30 - 13:55
PRECISION MRNA DELIVERY: OPTIMISING LNP PLATFORMS FOR ENHANCED STABILITY AND TARGETED THERAPEUTIC APPLICATIONS
Micaela Vitor
Sanofi

Micaela Vitor

Sanofi

  • Refining critical process parameters to scale mRNA-LNP manufacturing while protecting product integrity
  • Stabilising mRNA-LNPs with advanced formulation strategies that extend shelf-life across storage conditions
  • Decoding LNP targeting efficiency to resolve tissue-specific delivery across biological barriers
13:55 - 14:00
Q&A SESSION ON LNP PLATFORMS FOR STABLE AND TARGETED MRNA DELIVERY
14:00 - 14:25
IMPROVING OUTCOMES THROUGH TARGETED INTERVENTION: MODERN STRATEGIES FOR LOCO-REGIONAL CANCER THERAPY
Helena Kelly
Royal College of Surgeons in Ireland �– RCSI

Helena Kelly

Royal College of Surgeons in Ireland – RCSI

  • Advancing catheter-based, embolic, and image-guided systems for high-dose local tumour therapy
  • Integrating formulation factors such as viscosity and release kinetics to improve tumour penetration
  • Utilising device-enabled delivery to overcome tumour barriers and personalise solid tumour care
14:25 - 14:30
Q&A SESSION ON DEVICE-ENABLED LOCO-REGIONAL THERAPY
14:30 - 14:55
ON-BODY INJECTORS AND THE 2 ML MYTH: HOW SUBCUTANEOUS VOLUME MISCONCEPTIONS ARE CONSTRAINING DRUG DELIVERY AND DEVELOPMENT
Mehul Desai
Enable Injections, Inc.

Mehul Desai

Enable Injections, Inc.

  • Identifying how subcutaneous volume myths have shaped high-dose development choices
  • Analysing surveys of nurses, pharmacists, and patients on challenges with large-volume injections
  • Evaluating on-body injectors to ease administration and de-risk delivery development
14:55 - 15:00
Q&A SESSION ON SUBCUTANEOUS ON-BODY INJECTORS
15:00 - 15:20
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:20 - 15:50
PANEL DISCUSSION ON ORAL BIOLOGICS DELIVERY: CURRENT CHALLENGES AND EMERGING SOLUTIONS
  • Weighing whether oral biologics can rival injectable efficacy and reshape industry economics as regulators adapt approval frameworks
  • Rectifying stability and appearance challenges in oral formulations while expanding bioavailability options across available delivery systems
  • Safeguarding biotherapeutic stability across the lifecycle while balancing efficacy, safety, and immunogenicity through emerging precision delivery approaches

Kenneth Yongabi Anchang | Imo State University

Rudra Pratap Singh Rajput | Royal College of Pharmacy

Bindiya Chauhan | SGT University

15:50 - 16:15
PROBING LIPID ORDER IN LNPs FOR RNA DELIVERY WITH LAURDAN SPECTROSCOPY
Katharina Beck
Universität Augsburg – Projekt LISO

Katharina Beck

Universität Augsburg – Projekt LISO

  • Investigating lipid structures in RNA LNPs using temperature-sensitive fluorescent dyes
  • Quantifying lipid order with Laurdan to assess nanoparticle stability and membrane density
  • Mapping correlations between lipid order, efficacy, and storage resilience in RNA carriers
16:15 - 16:20
Q&A SESSION ON LNP STRUCTURE, STABILITY, AND RNA DELIVERY INSIGHTS
16:20 - 16:45
UTAC: ENGINEERING A BISPECIFIC THAT CONVERTS CLINICAL ANTIBODIES INTO ORAL FORMULATIONS USING ACTIVE RETRO-TRANSCYTOSIS
Maurits Kleijnen
Intract Pharma Ltd.

Maurits Kleijnen

Intract Pharma Ltd.

  • Designing UTAC bispecifics to ferry clinical antibodies from the gut lumen into the bloodstream
  • Co-formulating UTAC with clinical IgG to achieve high oral bioavailability in mice
  • Presenting macaque pilot data supporting active retro-transcytosis for oral biologics
16:45 - 16:50
Q&A SESSION ON UTAC-ENABLED ORAL ANTIBODY DELIVERY
16:50 - 17:15
HIGH-RESOLUTION TARGET VALIDATION FOR DRUG DELIVERY USING SPATIAL CELL SORTING
Amos Lee
Meteor Biotech

Amos Lee

Meteor Biotech

  • Enriching rare driver and responder cell states by spatial sorting from intact tissues
  • Generating cell-state multi-omics datasets from selected cells to confirm targets and on-target signatures
  • De-risking translation by converting insights into actionable biomarkers and cell-reach guidance
17:15 - 17:20
Q&A SESSION ON SPATIAL CELL SORTING FOR VALIDATION
17:20 - 18:20
NETWORKING DRINKS RECEPTION
DAY 2 :
THURSDAY, 3 SEPTEMBER, 2026
08:00 - 08:30
MORNING REFRESHMENTS
08:30 - 08:40
OPENING ADDRESS
08:40 - 09:10
PANEL DISCUSSION ON THE EUROPEAN DRUG DELIVERY SUMMIT
09:10 - 09:35
A NOVEL, TARGETED INTRACELLULAR DELIVERY TECHNOLOGY FOR PROTEIN THERAPEUTICS
Marie McAvoy
NanoSyrinx

Marie McAvoy

NanoSyrinx

  • Introducing nanosyringes for precise intracellular protein therapeutic delivery
  • Unlocking new potential for drugging currently inaccessible intracellular targets
  • Leveraging synthetic biology to enable novel modalities for intracellular therapies
09:35 - 09:40
Q&A SESSION ON INTRACELLULAR DELIVERY FOR PROTEIN THERAPEUTICS
09:40 - 10:05
CAVEOLAE PUMPING ACROSS THE ENDOTHELIUM TO BOOST PRECISION DRUG DELIVERY, POTENCY, AND EFFICACY
Jan Schnitzer
Proteogenomics Research Institute for Systems Medicine (PRISM)

Jan Schnitzer

Proteogenomics Research Institute for Systems Medicine (PRISM)

  • Examining endothelial barriers that limit targeting efficiency and heighten systemic toxicity
  • Targeting caveolae to enable precision extravasation of therapeutics across the endothelium
  • Enhancing drug concentration and therapeutic impact through active endothelial transport mechanisms
10:05 - 10:10
Q&A SESSION ON ENDOTHELIAL TARGETING FOR ENHANCED DRUG POTENCY
10:10 - 10:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
10:30 - 10:55
ORAL MICROSPHERE TECHNOLOGIES: ENABLING CONTROLLED AND MULTI-PHASE DRUG DELIVERY FOR PATIENTS WITH SWALLOWING CHALLENGES
Peter Zeng
Wisdrug AG

Peter Zeng

Wisdrug AG

  • Profiling oral microsphere platform capabilities for controlled and multi-phase drug release
  • Formulating paediatric prednisone and dual extended-release suspensions with oral microsphere platforms
  • Characterising microsphere performance across metformin product portfolios for dysphagia management
10:55 - 11:00
Q&A SESSION ON ORAL MICROSPHERE PLATFORMS FOR MULTI-PHASE DRUG RELEASE
11:00 - 11:25
FEASIBILITY ASSESSMENTS: PARTNERING EARLY TO MITIGATE COMBINATION PRODUCT DEVELOPMENT RISKS AND IMPROVE SPEED-TO-MARKET
Celine Wassaf
Becton Dickinson (BD)

Celine Wassaf

Becton Dickinson (BD)

  • Pinpointing key risks in combination product and wearable injector development strategies
  • Illustrating how early feasibility assessments de-risk device and drug compatibility issues
  • Highlighting case studies on data-driven collaboration to reduce time-to-market obstacles
11:25 - 11:30
Q&A SESSION ON EARLY PARTNERING TO DE-RISK COMBINATION PRODUCTS
11:30 - 11:55
UNLOCKING THE POTENTIAL OF INTRA-TISSUE DELIVERY FOR ADVANCED THERAPIES, PHARMACEUTICALS, AND OTHER THERAPEUTIC PAYLOADS
Ricardo Baptista
SmartCella Holding AB

Ricardo Baptista

SmartCella Holding AB

  • Deploying catheter-based delivery for precise endovascular intra-tissue administration
  • Accessing hard-to-reach tumours, tissues, and organs while preserving vascular integrity
  • Enabling repeatable image-guided local dosing with reduced systemic exposure at scale
11:55 - 12:00
Q&A SESSION ON INTRA-TISSUE DELIVERY
12:00 - 12:25
BEYOND THE FORMULATION: CLOSING THE ADOPTION GAP FOR NEXT-GEN DRUG DELIVERY SYSTEMS
Andreas Baier
Ergonomics Factory

Andreas Baier

Ergonomics Factory

  • Diagnosing why approved delivery platforms can remain invisible in real-world clinical uptake
  • Aligning clinical, R&D, and commercial teams early to de-risk adoption and value evidence
  • Applying stakeholder insights and interface engineering to address the needs of regulators, payers, and patients
12:25 - 12:30
Q&A SESSION ON CLOSING THE ADOPTION GAP FOR DEVICES
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE EUROPEAN DRUG DELIVERY SUMMIT
13:30 - 13:55
NANOFITINS FOR SELECTIVE AND ENHANCED DELIVERY OF NUCLEIC ACIDS
Victor Roullier
Affilogic

Victor Roullier

Affilogic

  • Engineering hyperstable protein scaffolds to target specific cell types for internalisation and BBB crossing
  • Coupling Nanofitins with siRNAs to achieve efficient gene knockdown in targeted cells, including those in the brain
  • Boosting mRNA-encoded protein function hundredfold by conjugating Nanofitins with lipid nanoparticles
13:55 - 14:00
Q&A SESSION ON NANOFITIN-MEDIATED NUCLEIC ACID DELIVERY
14:00 - 14:25
A NEW APPROACH TO NOSE-TO-BRAIN DELIVERY – NOSEPLUG AS A SUSTAINED-RELEASE CARRIER IN THE VESTIBULUM
Peter Åhnblad
Hogne AB

Peter Åhnblad

Hogne AB

  • Exploiting mucociliary motion to guide delivery with in-place vestibular device design
  • Stimulating olfactory and trigeminal pathways to enhance brain-targeted uptake efficacy
  • Controlling release kinetics for both immediate and sustained nose-to-brain distribution
14:25 - 14:30
Q&A SESSION ON NASAL DEVICES FOR SUSTAINED BRAIN DELIVERY
14:30 - 15:00
RESERVED PRESENTATION
15:00 - 15:15
FEEDBACK AND RAFFLE DRAW
15:15 - 15:30
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.